Clinical trials: Poor Graft Function, open to volunteers
Graft Failure, Poor Graft Function
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft…
- Trial name
- NCT06569082
- Testing
- CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
MSC
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective approach for treating both benign and malignant blood disorders.
- Trial name
- NCT06171906
- Testing
- mesenchymal stromal cells
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- ShiCang Yu
Blood And Marrow Transplantation
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
- Trial name
- NCT02438904
- Testing
- CD34 Positive Stem Cell Infusion, Miltenyi device
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Poor Graft Function, Aplastic Anemia Idiopathic
REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2
Allogeneic stem cell transplantation involves the transplanting of donor blood stem cells into a recipient, this is performed mainly for the treatment of blood cancers.
- Trial name
- RESELECT2 (NCT06607367)
- Testing
- Ruxolitinib (JAKAVI®), Eltrombopag (Revolade®)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melbourne Health
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Poor Graft Function
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
This study is conducted in a prospective, single-center clinical design and is divided into two stages: dose escalation and dose extension.
- Trial name
- NCT06792682
- Testing
- Dose escalation, Dose extension
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Poor Graft Function
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT
This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
- Trial name
- NCT05669079
- Testing
- decitabine, umbilical cord blood, Granulocyte-colony stimulating factor
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University